Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Comparision of the clinicopathological characteristics between the 220 patients in the NACT-IDS and PDS group with stage IIIC and IV epithelial ovarian cancer

From: Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Characteristics PDS group (n = 141) NACT group(n = 79) P value
Age (years), mean ± SD 55.99 ± 11.10 57.08 ± 10.38 0.526
Pathology type    0.390
 Serous carcinoma 117(83.0%) 69(87.3%)  
 Other types 24(17.0%) 10(12.7%)  
Stage    0.123
 IIIC 119(84.4%) 60(75.9%)  
 IV 22(15.6%) 19(24.1%)  
Histology grade*    0.035
 G1 2(1.4%) 0(0%)  
 G2 27(19.4%) 6(7.7%)  
 G3 110(79.1%) 72(92.3%)  
Initial CA125 level*    0.036
 <500 U/ml 60(42.6%) 22(28.2%)  
  ≥ 500 U/ml 81(57.4%) 56(71.8%)  
 Pleural effusion 12(8.5%) 14(17.7%) 0.042
 Liver metastasis 15(10.6%) 6(7.6%) 0.461
Tumor distribution    < 0.001
 Localized 38(27.0%) 0 (0%)  
 Diffuse 103(73.0%) 79 (100%)  
lymphadenectomy 107(75.9%) 60(75.9%) 0.992
Residual disease    0.071
 None, R0 46 (32.6%) 34(43.0%)  
 <1 cm,R1 44 (31.2%) 28(35.4%)  
  ≥ 1 cm,R2 51 (36.2%) 17(21.5%)  
 Lymph node metastasis* 69(61.1%) 20(32.3%) < 0.001
  1. Histology grade* refers to 3 cases with unknown histology grade due to difficult histology recognition
  2. Initial CA125 level* refers to 1 case with unknown Initial CA125 level
  3. Lymph node metastasis* refers to 28 cases in PDS group and 17 cases in NACT group respectively had unknown lymph node accessment as they didn't undergo lymphadenectomy